[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649079":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":11,"responsibleParty":39,"collaborators":11,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":11,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":67,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":11},{"fullName":5,"class":6},"University of Washington","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Finasteride group","EXPERIMENTAL",null,[13],"Drug: Finasteride 1 mg",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo group","PLACEBO_COMPARATOR",[18],"Drug: Placebo Control",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Finasteride 1 mg","Patients randomized to the experimental group will receive oral Finasteride 1 mg, taken daily, for two weeks",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo Control","Patients randomized to the placebo group will receive one pill containing no active medicine, taken daily, for two weeks.",[15],[30],{"name":31,"affiliation":5,"role":32},"Corey Schiffman, MD","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Anastasia Whitson","CONTACT","206-755-7847","whitsa@uw.edu",{"type":32,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Corey Schiffman","Assistant Professor: School of Medicine, Orthopaedics and Sports Medicine","100649079","phase-4-finasteride-and-cutibacterium-100649079",false,"NCT07731802","Finasteride and Cutibacterium","Inclusion We will include the group most impacted by PJI\n\n* Adult males\n* Age between 18 and 65 Exclusion\n* History of cryptorchidism, hypospadias, or other congenital abnormality of male reproductive tract\n* Female sex\n* Age younger than 18 or older than 65\n* Current use of Finasteride or other 5-alpha reductase inhibitors\n* Current use of hormone replacement medications such as testosterone\n* Recent antibiotic use within 3 months\n* Have had a negative reaction to oral Finasteride before\n* Recent use of acne treatment within 3 months\n* Self-report very sensitive skin\n* Allergic to chlorhexidine or isopropyl alcohol\n* Have open wounds on both shoulders",true,"MALE","18 Years","65 Years",{"count":53,"type":54},40,"ESTIMATED","INTERVENTIONAL",[57],"PHASE4","High levels of Testosterone causes high amounts of skin bacteria (Cutibacterium Acnes) which can go into the skin during a shoulder replacement surgery and cause a terrible infection.\n\nThe goal of this experiment is to have participants take Finasteride, a medication that blocks testosterone production, for 2 weeks and evaluate the following:\n\n* Blood levels of testosterone\n* Amount of bacteria on the skin.\n\nParticipants will:\n\n* Be assigned to take Finasteride, or a placebo (a look-alike pill with no active medicine) once daily, for 2 weeks\n* Have a small sample of their blood collected and their skin swabbed with a Q-tip to determine Testosterone levels and bacteria on the skin\n* Blood draw and skin testing will take place before starting Finasteride or the placebo (day 0) and at the end of the experiment (day 14).",[60,61,62],"Dihydrotestosterone","Periprosthetic Joint Infection (PJI)","Cutibacterium Acnes",[64,65,66],"placebo","blood draw","skin culture","NOT_YET_RECRUITING","2026-07-23",{"date":70,"type":71},"2026-07-28","ACTUAL",{"date":73,"type":54},"2026-08-31",{"date":75,"type":54},"2027-08-31",{"name":5,"class":6}]